1265 Serum and biliary cytokeratin fragment CYFRA 21-1, CEA, and CA 19.9 as tumor markers for cholangiocarcinoma

The Value of Molecular Biomarkers in Biliary Tract Cancer in the Era of Targeted Therapy

“…22,29 However, the assay used for measuring CA 19-9 can affect the results. Hotakainen et al, on comparison of 3 immunoassays for CA 19-9, showed that Abbott i2000 Architect (CA 19-9XR assay) measures lower concentrations than the other 2 assays (Roche Elecsys 2010 and Bayer Immuno 1 analyzers) in benign conditions and thus may provide the best discrimination between benign and malignant gastrointestinal (GI) disease.…”